Treats pulmonary arterial hypertension (PAH) (WHO Group 1). ANDA 216531, held by Aurobindo Pharma. Ambrisentan.
As of Nov 21, 2026, ANDA 216531 (Ambrisentan), held by Aurobindo Pharma, was first approved by FDA on Jul 21, 2022, with 3 approved supplements and 0 published complete response letters.
Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2022 | Original application | Approved |
| Ambrisentan5MG · tablet;oral | Ambrisentan | Rx |
| Ambrisentan10MG · tablet;oral | Ambrisentan | Rx |
| Jul 18, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 4, 2025 | Supplement 2REMS | Approved | None posted |
| Aug 19, 2024 | Supplement 1REMS | Approved | None posted |
| Jul 21, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters